Difficult-to-Express Proteins Market Report 2026

The difficult-to-express proteins market size has grown rapidly in recent years. It will grow from $5.2 billion in 2025 to $5.79 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to growth in biologics research, limitations of traditional expression systems, academic protein research expansion, demand for membrane proteins, biotech funding growth.

The difficult-to-express proteins market size is expected to see rapid growth in the next few years. It will grow to $8.99 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to growth of protein therapeutics, innovation in expression technologies, demand for structural biology studies, increased pharma outsourcing, precision medicine research expansion. Major trends in the forecast period include increasing demand for complex protein expression, expansion of cell-free protein synthesis, growing use of fusion and tag technologies, rising application in drug discovery, adoption of advanced expression systems.

The growing demand for biopharmaceuticals is expected to drive the growth of the difficult-to-express proteins market in the coming years. This driver reflects the increasing global dependence on biologics, therapeutic proteins, and advanced biopharmaceutical modalities for treating a broad range of diseases. Demand is rising as patients and healthcare systems increasingly favor precision medicine and biologic therapies over conventional small-molecule drugs. The difficult-to-express proteins market supports this shift by enabling the production of complex proteins, including multi-domain proteins, antibody fragments, fusion proteins, and proteins requiring post-translational modifications, which are essential for advanced therapeutic applications. For instance, in July 2025, according to Sartorius, a Germany-based life science technology company, global biopharmaceutical drug sales increased by approximately 9% to reach USD 458 billion in 2024, accounting for 41% of the total pharmaceutical market, up from 40% in 2023. Therefore, the rising demand for biopharmaceuticals is driving the growth of the difficult-to-express proteins market.

The development of innovative technologies is a key trend gaining traction in the difficult-to-express proteins market. Leading companies are focusing on advancing novel technologies to maintain their competitive position and improve protein design and expression capabilities. For instance, in January 2023, Evozyne, a US-based biotechnology company, developed an advanced artificial intelligence model known as the Protein Transformer Variational AutoEncoder for therapeutic protein design. This approach establishes a framework for training and deploying large language models in biological applications, representing a novel deep-learning strategy that enables data-driven engineering of proteins with customized functionality.

In July 2023, Biovian, a Finland-based contract development and manufacturing organization specializing in biopharmaceuticals, invested over $53.249 million (€50 million) to expand its manufacturing facility in Turku. This expansion is intended to increase production capacity and operational flexibility to support the development and large-scale manufacturing of biologics, viral vectors, and microbial proteins. The project includes the addition of a new 6,400-square-meter facility equipped with advanced infrastructure and dedicated cleanroom spaces for bulk drug substance and final drug product manufacturing, enabling larger and more complex viral vector and microbial protein programs.

Major companies operating in the difficult-to-express proteins market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group Ltd, Catalent Inc., Sartorius AG, Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Samsung Biologics Co. Ltd., Bio-Techne Corp., GenScript Biotech Corporation, Ajinomoto Bio-Pharma Services, Novasep Holding SAS, Rentschler Biopharma SE, BioLegend Inc., Codexis Inc., Enzo Biochem Inc., Sino Biological Inc., Horizon Discovery Ltd., Creative Biolabs Inc., OriGene Technologies Inc., Celonic AG, Cube Biotech GmbH, Lucigen Corporation, Batavia Biosciences Inc., Cytovance Biologics Inc., Alloy Therapeutics Inc., Aragen Bioscience Inc., Selexis SA, LifeSensors Inc., Bionova Scientific Inc.

North America was the largest region in the difficult-to-express proteins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the difficult-to-express proteins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the difficult-to-express proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the difficult-to-express proteins market by increasing costs of imported reagents, expression kits, laboratory equipment, and bioprocessing tools. Research institutions and biotech companies in developed regions are most affected due to reliance on imported materials, while emerging markets face higher setup costs. These tariffs increase research expenses. However, they support local reagent production and regional biotech manufacturing capabilities.

The difficult-to-express proteins market research report is one of a series of new reports that provides difficult-to-express proteins market statistics, including difficult-to-express proteins industry global market size, regional shares, competitors with a difficult-to-express proteins market share, detailed difficult-to-express proteins market segments, market trends and opportunities, and any further data you may need to thrive in the difficult-to-express proteins industry. This difficult-to-express proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Difficult-to-express proteins are proteins that are challenging to produce in large quantities or at high yield using conventional heterologous protein expression systems. These proteins are widely used in research to study protein folding and stability, develop novel therapeutics, and support biochemical and drug-related studies.

The main types of difficult-to-express proteins include proteases, kinases, membrane proteins, and others. Proteases are enzymes that catalyze the cleavage of peptide bonds in proteins and serve as important tools in peptide research due to their ability to break proteins into smaller fragments, enabling mass spectrometry analysis and supporting the study and treatment of conditions such as inflammation, sepsis, digestive disorders, cystic fibrosis, retinal diseases, and others. Different expression challenges include disulfide-bonded protein expression, membrane protein expression, toxic protein expression, and target protein insolubility. These challenges are addressed using technologies such as cell-free protein synthesis, prokaryotic expression systems, small ubiquitin-like modifier (SUMO) fusion systems, gene fusion systems, and others. Difficult-to-express proteins are applied in areas including drug discovery, protein purification, protein therapeutics, disease diagnostics and monitoring, and related fields.

The difficult-to-express proteins market consists of revenues earned by entities by providing code optimization, fusion tags, post-translational modification, inducible expression systems, and co-expression chaperones. The market value includes the value of related goods sold by the service provider or included within the service offering. The difficult-to-express protein market also includes the sales of toxoids, antibody fragments, multi-domain proteins, and post-translational modified proteins. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.